In the latest trading session, Amgen (AMGN) closed at $294.76, marking a -1.17% move from the previous day.
This week's Undercovered Dozen spotlights 12 lesser-known stocks with compelling investment theses, spanning micro-nuclear, luxury, biotech, and high-yield BDCs. Highlighted opportunities include NANO Nuclear Energy's niche potential, Christian Dior SE's LVMH exposure, and Harrow's explosive growth in ophthalmic pharmaceuticals. Coca-Cola and Ares Capital are flagged as overvalued or increasingly risky, with warnings of unsustainable growth and looming corrections for investors.
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
![]() AMG 11 months ago | Other | €2.25 Per Share |
![]() AMG 16 May 2024 | Other | €2.25 Per Share |
![]() AMG 15 Feb 2024 | Other | €2.25 Per Share |
![]() AMG 16 Nov 2023 | Other | €2.13 Per Share |
![]() AMG 17 Aug 2023 | Other | €2.13 Per Share |
5 Aug 2025 (In 2 weeks) Date | | 5.26 Cons. EPS | - EPS |
4 Aug 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
4 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
![]() AMG 11 months ago | Other | €2.25 Per Share |
![]() AMG 16 May 2024 | Other | €2.25 Per Share |
![]() AMG 15 Feb 2024 | Other | €2.25 Per Share |
![]() AMG 16 Nov 2023 | Other | €2.13 Per Share |
![]() AMG 17 Aug 2023 | Other | €2.13 Per Share |
5 Aug 2025 (In 2 weeks) Date | | 5.26 Cons. EPS | - EPS |
4 Aug 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
4 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Robert A. Bradway CEO | XFRA Exchange | US0311621009 ISIN |
US Country | 28,000 Employees | 16 May 2025 Last Dividend | 22 Nov 1999 Last Split | 17 Jun 1983 IPO Date |
Amgen Inc. is a global leader in biotechnology, focusing on the discovery, development, manufacture, and delivery of human therapeutics. The company has a comprehensive portfolio of treatment options targeting various diseases and conditions, ranging from oncology and osteoporosis to cardiovascular diseases and inflammatory disorders. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen serves healthcare providers worldwide, including physicians' clinics, dialysis centers, hospitals, and pharmacies. Its distribution network encompasses pharmaceutical wholesale distributors and direct-to-consumer channels. Amgen’s collaborative efforts extend to several high-profile partnerships with other pharmaceutical giants, including AstraZeneca, Novartis Pharma AG, UCB, Kyowa Kirin Co., Ltd., and BeiGene, Ltd., aiming at the expansion and development of innovative therapies.